July 7 - Lilly, Boehringer's heart failure milestone, 5 FDA decisions to watch and Nestle's marketing pact

WHO backs Roche, Sanofi drugs for COVID-19 after research ups and downs; 5 FDA decisions to watch in the third quarter; Nestlé joins Seres in deal to market microbiome drug; FDA knocks back diabetes prevention drug, crushing its maker's shares View online | Signup | Forward

Commercialization weekly July​ 7,​ 2021 | This week's commercialization news and insights for biopharma leaders   BROUGHT TO YOU BY — MedPoint Be First in Virtual Speaker Programs MedPoint Digital leads in service, technology and knowing what it takes to deliver results. Read the whitepaper.   Lilly, Boehringer say diabetes drug first to succeed in hard-to-treat heart failure The results are a potentially significant finding that could help change how heart failure patients with preserved ejection fraction are treated, and will support the companies' application for the drug's approval. WHO backs Roche, Sanofi drugs for COVID-19 after research ups and downs Once long-shot experiments in the rush to repurpose drugs for COVID-19, both Actemra and Kevzara could become more widely used, renewing questions around cost and access. 5 FDA decisions to watch in the third quarter The agency is under pressure to grant full approvals to two coronavirus vaccines and faces important questions on how to handle the next Alzheimer's drugs after Aduhelm. Sponsored Content by IQVIA Reveal the "hidden clinical leaders" who drive HCP network adoption Optimizing your insights into HCP/thought leader networks is critical for promoting new treatments. Nestlé joins Seres in deal to market microbiome drug The health science unit at Nestlé may pay more than $500 million to secure rights in the U.S. and Canada for SER-109, a spore-filled capsule meant for patients with recurrent C. diff infections. FDA knocks back diabetes prevention drug, crushing its maker's shares Provention Bio said it expects to collect data that could address the FDA's concerns before the end of September. In the meantime, though, the company's shares have taken another hit. CureVac vows to seek vaccine approval despite low efficacy in COVID-19 study Final results from CureVac's large Phase 3 study showed an overall efficacy of just 48%, although the German biotech emphasized stronger protection against more severe disease and in younger adults. Read more news From Our Library Trendline The ongoing developments in the COVID-19 vaccine Trendline What you need to know about oncology's research boom View all resources What We're Reading FiercePharma Is pharma's halo slipping? Industry image continues to slide in latest Harris Poll CNBC Biden's new Covid vaccine push focuses on workers, students, delta variant Endpoints News FDA shoots down petition to stall generic versions of Bristol Myers’ blockbuster chemo Abraxane Suggest a story we should read Upcoming Event Demystifying the Role of Data Analytics in Digital Transformation July 21, 2021 - July 21, 2021 | Webinar 2pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Commercialization Weekly with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Commercialization Weekly. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Commercialization Weekly is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip